Drug intelligence / Profile preview

AD-211-L

Development stage: Phase 1
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-211-L is an Addpharma-sponsored oral dose variant within the AD-211 pain-treatment program, which is described in the provided trial context as a celecoxib + eperisone combination. It is being evaluated in a randomized Phase 2 dose-optimization study for knee osteoarthritis. Celecoxib is a selective cyclooxygenase-2 inhibitor that reduces prostaglandin-mediated pain and inflammation; eperisone is used as a centrally acting skeletal-muscle relaxant. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550231))

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on AD-211-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-211-L.